27 Biggest Biotech Companies in the World

Here you can find the list of biggest biotech companies in the world based on the Total Revenue.

Amgen Inc is the world’s no 1 biotech company in the world with a revenue of  $ 25 Billion from United states followed by Gilead Sciences, Inc.

List of Biggest Biotech Companies in the World

Here is the largest biotech companies in the world which are sorted out based on the total Revenue. list of biotech companies in the world.

So these are the leading biotech companies in the world based on the size.

Amgen – Largest biotech company in the world

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

The company has presence in approximately 100 countries and regions worldwide and innovative medicines have reached millions of people in the fight against serious illnesses. Biotech company focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation. The company medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Biogen Inc

One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp.

Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease.

Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.